Nrp2 inhibition results in abnormal tail dermal lymphangiogenesis. (A–L) Developmental time course of tail dermal lymphangiogenesis by whole-mount LYVE-1 immunohistochemistry at P2, 4, 6, and 8. The tails are imaged to show the overall lymphatic network pattern (A–D), to demonstrate representative ring complexes (E–H), and to demonstrate tip cells extending from the complexes (I–L). (M–U) Treatment with anti-Nrp2^B results in alteration of lymphangiogenesis. The lymphatics in anti-Nrp2^B–treated tails at P8 after treatment at P1, 3, and 5. 3D projections of the confocal images in control (O) and anti-Nrp2^B–treated ring complexes (S) in N and R, respectively. The bottom projection is rotated 45° to provide depth perspective. (P and T) Representative examples of junctions with dots to denote tallied branch points in control (P) and anti-Nrp2^B (T)–treated tails. (U) Quantification of branch points in ring complexes of control and anti-Nrp2^B–treated tails (n = 10 junctions/animal for six animals per condition; *, P < 0.0001). Error bars indicate SEM. Bars: (A–D, M, and Q) 250 µm; (E–H) 60 µm; (I–L) 25 µm; (N–R) 75 µm.